Clinical Trial

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography \[PET\]/magnetic resonance imaging \[MRI\]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05-26 -> 2027-04-27 2026-07-02
minor Completion pushed: 2026-05-26 -> 2027-04-27 2026-07-02
Trial Details
NCT Number NCT05376878
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Enrollment 10 participants
Start Date 2022-12-21
Primary Completion 2027-04-27 (estimated)
Study Completion 2027-04-27 (estimated)
Updated on ClinicalTrials.gov 2026-07-01